Table 1.
Study features in the systematic review.
| Literature | Diagnosis criteria | Subjects (n) | Ethnicity | VitD dose (IU/day) | Intervention | Follow-up time (weeks) | Baseline VitD (ng/mL)a | Final VitD (ng/mL)a |
|---|---|---|---|---|---|---|---|---|
| Rahimi-Ardabili,15 2013 | Rotterdam | 24/26 | Asian: 100% | 2500 | CholecalciferolPlacebo | 8 | 6.9 ± 2.87.3 ± 2.9 | 23.4 ± 6.148.57 ± 3.98 |
| Raja-Khan,18 2014 | NIH | 13/15 | N/A | 12000 | CholecalciferolPlacebo | 12 | 19.9 ± 9.522.2 ± 6.9 | 67.36 ± 28.6222.45 ± 7.02 |
| Asemi-1,16 2015 | Rotterdam | 26/26 | Asian: 100% | 7143 | CholecalciferolPlacebo | 8 | 11.6 ± 4.713.9 ± 2.0 | 23.4 ± 7.114.2 ± 2.2 |
| Asemi-2,16 2015 | Rotterdam | 26/26 | Asian: 100% | 7143 | Cholecalciferol+ Calcium Placebo + Calcium | 8 | 15.1 ± 3.614.0 ± 4.1 | 26.8 ± 7.814.4 ± 4.7 |
| Garg,21 2015 | Rotterdam | 15/17 | Asian: 100% | 4000 | Cholecalciferol + MET Placebo + MET | 24 | 7.7 ± 6.056.8 ± 2.46 | 31.5 ± 13.886.7 ± 2.31 |
| Irani,14 2015 | Rotterdam | 35/18 | Vitamin D group: Hispanic, 69.4%; Asian, 25%; Black, 5.5%; Placebo group: Hispanic, 72.2%; Asian, 22.2%; Black, 5.5% | 7143 | CholecalciferolPlacebo | 8 | 16.3 ± 0.917.0 ± 1.8 | 43.2 ± 2.417.4 ± 1.9 |
| Foroozanfard,13 2017 | Rotterdam | 30/30/30 | Asian: 100% | 40001000 | Cholecalciferol (high-dose) + METCholecalciferol (lose-dose) + METPlacebo + MET | 12 | 13.5 ± 3.114.0 ± 4.614.0 ± 3.5 | 24.3 ± 3.720.7 ± 6.214.1 ± 3.6 |
| Maktabi,17 2017 | Rotterdam | 35/35 | Asian: 100% | 3571 | CholecalciferolPlacebo | 12 | 12.8 ± 4.514.5 ± 5.1 | 27.5 ± 9.814.4 ± 5.2 |
| Dastorani,12 2018 | Rotterdam | 20/20 | Asian: 100% | 3571 | CholecalciferolPlacebo | 8 | 10.5 ± 2.511.0 ± 2.4 | 21.7 ± 5.910.9 ± 2.1 |
aMean ± SD
NIH, the 1990 National Institutes of Health criterion; MET, metformin; VitD, vitamin D; N/A, not applicable; SD, standard deviation.